i-bodies


i-bodies are a promising, novel class of protein therapeutics that offer a new and potentially more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

i-bodies, have the exceptional targeting and antigen binding properties and carry out the functional role of recognising and binding to other molecules/antigens including disease targets to produce a therapeutic effect.

i-bodies are designed so that they mimic the shape of the antigen binding domain of shark antibodies and their key stability features; these characteristics are engineered into a human protein. As unique compounds, i-bodies have a shark-like long binding loop that is absent in human antibodies and other next generation antibodies. This long binding loop and the human protein i-body scaffold form the i-body.

 

i-body key properties and benefits

  • High target specificity and high affinity for their target
  • Small proteins; 10% the size if a typical human antibody
  • Highly stable to proteases, high temperatures and low pH
  • Long loop for target cavity binding and alternative epitopes
  • Human protein – reduces risk of immune response

 


i-bodies combine the high target specificity and affinity advantages of antibodies with the beneficial features of small molecule drugs. These features also enables i-bodies to overcome challenging targets.

Small
Molecule
Conventional
Antibody
AdAlta
i-body
High selectivity-specificity
Low toxicity: no off target effects
Cavity binding
Stability
Alternative routes of administration
Easy to manufacture
Speed & risk of development

 


Overcoming challenging targets

i-bodies can recognise and bind to a diverse range of different therapeutically-relevant targets including those that are difficult/intractable to access by current antibody therapies such as G-protein coupled receptors (GPCRs) and ion channels, as result of the long binding loop that is lacking in traditional antibodies.

G-protein coupled receptors (GPCRs) and ion channels have traditionally been targeted by small molecule drugs, which account for and are targeted by approximately 40% of all drugs currently on the market. Small molecules can have an increased risk of toxicity and off target side effects due to their lack of specificity. With their high affinity and specificity and long binding loop, the i-body can access GPCRs and ion channels without the off-target side effects common with small molecule drugs.

Learn more about i-bodies.